The 'world' of soft tissue sarcomas is a highly complex one, due to the large range of tumor types, each of which is characterized by specific features in terms of its epidemiology, pathology diagnosis, clinical behavior, therapy and biomarker pattern (of both diagnostic and therapeutic value). This book offers a practical, clearly structured reference guide, covering all of these aspects for each soft tissue tumor. Thanks to the consistent and user-friendly format, readers can quickly and easily find the information they need; in addition, up-to-date and authoritative literature information helps them to pursue further research. 

Overall, this book offers professionals and residents in the fields of oncology, surgery, and pathology an essential guide for study, review, and everyday clinical practice.

Prof. Mocellin specialized in General Surgery in Padua in 1998, and received his Ph.D. in Oncology and Surgical Oncology from the University of Padua, Italy, in 2004.

Currently he is a Surgical Oncologist at the Melanoma and Sarcoma Unit of the Istituto Oncologico Veneto - Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS) in Padua, and a Professor of Surgery at the Department of Surgery Oncology and Gastroenterology (DiSCOG), University of Padua, Italy.

Since 2000, he authored more than 195 scientific articles published in international peer-reviewed medical journals, with a total impact factor of more than 1200, more than 9000 citations and an H-index equal to 52.

He is a member of the editorial board of several international peer-reviewed medical journals, and is an editor for the Cochrane Collaboration (the world's leading organization for medical meta-analysis).

1;Preface;62;Contents;83;Part I: Basics on Soft Tissue Tumors;173.1;1: Definition;183.1.1;Suggested Readings;193.2;2: Epidemiology and Presentation;203.2.1;Suggested Readings;243.3;3: Etiology and Predisposition;253.3.1;Suggested Readings;293.4;4: Pathology;303.4.1;Suggested Readings;373.5;5: Biomarkers;383.5.1;Suggested Readings;383.6;6: Prognosis;403.6.1;Suggested Readings;453.7;7: Therapy;463.7.1;Surgery;463.7.2;Radiotherapy;493.7.3;Chemotherapy;513.7.4;Target Therapy;553.7.5;Immunotherapy;563.7.6;Suggested Readings;574;Part II: Soft Tissue Tumors;614.1;8: Acoustic Neuroma;624.1.1;Definition;624.1.2;Epidemiology and Presentation;624.1.3;Etiology and Predisposition;634.1.4;Pathology;644.1.5;Biomarkers;644.1.6;Prognosis;644.1.7;Therapy;654.1.8;Suggested Readings;654.2;9: Acquired Digital Fibrokeratoma;664.2.1;Definition;664.2.2;Epidemiology and Presentation;664.2.3;Pathology;664.2.4;Biomarkers;674.2.5;Prognosis;674.2.6;Therapy;674.2.7;Suggested Readings;674.3;10: Acral Fibromyxoma;684.3.1;Definition;684.3.2;Epidemiology and Presentation;684.3.3;Pathology;684.3.4;Biomarkers;694.3.5;Prognosis;694.3.6;Therapy;694.3.7;Suggested Readings;694.4;11: Adult Fibrosarcoma;704.4.1;Definition;704.4.2;Epidemiology and Presentation;704.4.3;Pathology;704.4.4;Biomarkers;714.4.5;Prognosis;714.4.6;Therapy;714.4.7;Suggested Readings;724.5;12: Adult Rhabdomyoma;734.5.1;Definition;734.5.2;Epidemiology and Presentation;734.5.3;Pathology;734.5.4;Biomarkers;744.5.5;Prognosis;744.5.6;Therapy;744.6;13: Alveolar Rhabdomyosarcoma;754.6.1;Definition;754.6.2;Epidemiology and Presentation;754.6.3;Etiology and Predisposition;754.6.4;Pathology;764.6.5;Biomarkers;764.6.6;Prognosis;774.6.7;Therapy;774.6.8;Suggested Readings;774.7;14: Alveolar Soft Part Sarcoma;784.7.1;Definition;784.7.2;Epidemiology and Presentation;784.7.3;Pathology;784.7.4;Biomarkers;794.7.5;Prognosis;794.7.6;Therapy;804.7.7;Suggested Readings;814.8;15: Anastomosing Hemangioma;824.8.1;Definition;824.8.2;Epidemiology and Presentation;824.8.3;Pathology;824.8.4;Biomarkers;834.8.5;Prognosis;834.8.6;Therapy;834.8.7;Suggested Readings;834.9;16: Aneurysmal Fibrous Histiocytoma;844.9.1;Definition;844.9.2;Epidemiology and Presentation;844.9.3;Pathology;844.9.4;Biomarkers;854.9.5;Prognosis;854.9.6;Therapy;854.9.7;Suggested Readings;854.10;17: Angiofibroma;864.11;18: Angiofibroma of Soft Tissue;874.11.1;Definition;874.11.2;Epidemiology and Presentation;874.11.3;Pathology;874.11.4;Biomarkers;884.11.5;Prognosis;884.11.6;Therapy;884.11.7;Suggested Readings;894.12;19: Angiokeratoma;904.12.1;Definition;904.12.2;Epidemiology and Presentation;904.12.3;Pathology;904.12.4;Biomarkers;914.12.5;Prognosis;914.12.6;Therapy;914.12.7;Suggested Readings;914.13;20: Angioleiomyoma;924.13.1;Definition;924.13.2;Epidemiology and Presentation;924.13.3;Etiology and Predisposition;924.13.4;Pathology;934.13.5;Biomarkers;934.13.6;Prognosis;934.13.7;Therapy;934.13.8;Suggested Readings;934.14;21: Angiolipoma;944.14.1;Definition;944.14.2;Epidemiology and Presentation;944.14.3;Etiology and Predisposition;944.14.4;Pathology;954.14.5;Biomarkers;954.14.6;Prognosis;954.14.7;Therapy;954.14.8;Suggested Readings;954.15;22: Angiomatoid Fibrous Histiocytoma;964.15.1;Definition;964.15.2;Epidemiology and Presentation;964.15.3;Pathology;964.15.4;Biomarkers;974.15.5;Prognosis;984.15.6;Therapy;984.15.7;Suggested Readings;984.16;23: Angiomyofibroblastoma;994.16.1;Definition;994.16.2;Epidemiology and Presentation;994.16.3;Pathology;994.16.4;Biomarkers;1004.16.5;Prognosis;1004.16.6;Therapy;1004.16.7;Suggested Readings;1004.17;24: Angiomyolipoma;1014.17.1;Definition;1014.17.2;Epidemiology and Presentation;1014.17.3;Etiology and Predisposition;1014.17.4;Pathology;1024.17.5;Biomarkers;1024.17.6;Prognosis;1034.17.7;Therapy;1034.17.8;Suggested Readings;1034.18;25: Angiosarcoma;1044.18.1;Definition;104